MIF signal transduction initiated by binding to CD74

Journal of Experimental Medicine

Volumn 197, Issue 11, 2003, Pages 1467-1476

  Leng, Lin ^a   Metz, Christine N ^b   Fang, Yan ^a   Xu, Jing ^a   Donnelly, Seamas ^c   Baugh, John ^c   Delohery, Thomas ^d   Chen, Yibang ^e   Mitchell, Robert A ^f   Bucala, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b N Shore Long Isl Jewish Res Inst ^*  (United States)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Cytokine; Invariant chain; Macrophage migration inhibitory factor; MAP kinase; Receptor

Indexed keywords

CD70 ANTIGEN; CD74 ANTIGEN; LIGAND; MACROPHAGE MIGRATION INHIBITION FACTOR; MEMBRANE PROTEIN; MEMBRANE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISSOCIATION CONSTANT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOCOMPETENT CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; TARGET CELL; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; APOPTOSIS; CLONING, MOLECULAR; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; PROTEIN BINDING; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE;

EID: 12444285441     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20030286     Document Type: Article

References (63)

1. George, M., and J.H. Vaughn. 1962. In vitro cell migration as a model for delayed hypersensitivity. Proc. Soc. Exp. Biol. Med. 111:514-521.
2. David, J. 1966. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc. Natl. Acad. Sci. USA. 56:72-77.
3. Bloom, B.R., and B. Bennett. 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science. 153:80-82.
4. Weiser, W.Y., P.A. Temple, J.S. Witek-Giannotti, H.G. Remold, S.C. Clark, and J.R. David. 1989. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA. 86:7522-7526.
5. Bernhagen, J., T. Calandra, R.A. Mitchell, S.B. Martin, K.J. Tracey, W. Voelter, K.R. Manogue, A. Cerami, and P. Bucala. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 365:756-759.
6. Nishihira, J. 2000. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J. Interferon Cytokine Res. 9:751-756.
7. Metz, C., and R. Bucala. 2000. MIF. In Cytokine Reference. Academic Press, Inc., San Diego. 703-716.
8. Calandra, T., J. Bernhagen, R.A. Mitchell, and R. Bucala. 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179:1895-1902.
9. Bozza, M., A.R. Satoskar, G. Lin, B. Lu, A.A. Humbles, C. Gerard, and J.R. David. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189:341-346.
10. Mitchell, R.A., H. Liao, J. Chesney, G. Fingerle-Rowson, J. Baugh, J. David, and R. Bucala. 2002. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA. 99:345-350.
11. Nathan, C.F., H.G. Remold, and J.R. David. 1973. Characterization of a lymphocyte factor which alters macrophage function. J. Exp. Med. 137:275-288.
12. Jüttner, S., J. Bernhagen, C.N. Metz, M. Rollinghoff, R. Bucala, and A. Gessner. 1998. Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J. Immunol. 161:2383-2390.
13. de Jong, Y.P., A.C. Abadia-Molina, A.R. Satoskar, K. Clarke, S.T. Rietdijk, W.A. Faubion, E. Mizoguchi, C.N. Metz, M.A. Sahli, T. ten Hove, et al. 2001. Development of chronic colitis is dependent on the cytokine MIF. Nat. Immunol. 2:1061-1066.
14. Satoskar, A., M. Bozza, M. Rodriguez Sosa, G. Lin, and J.R. David. 2001. Migration inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect. Immun. 69:906-911.
15. Roger, T., J. David, M.P. Glauser, and T. Calandra. 2001. MIF regulates innate immune responses through modulation of toll-like receptor 4. Nature. 414:920-924.
16. Bernhagen, J., M. Bacher, T. Calandra, C.N. Metz, S.B. Doty, T. Donnelly, and R. Bucala. 1996. An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. J. Exp. Med. 183:277-282.
17. Bacher, M., C.N. Metz, T. Calandra, K. Mayer, J. Chesney, M. Lohoff, D. Gemsa, T. Donnelly, and R. Bucala. 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. USA. 93:7849-7854.
18. Donnelly, S.C., and R. Bucala. 1997. Macrophage migration inhibitory factor: a regulator of glucocorticoid activity with a critical role in inflammatory disease. Mol. Med. Today. 3:502-507.
19. Baugh, J.A., S. Chitnis, S.C. Donnelly, J. Monteiro, X. Lin, B.J. Plant, F. Wolfe, P.K. Gregersen, and R. Bucala. 2002. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun. 3:170-176.
20. Donn, R., Z. Aloufi, F. De Benedetti, C. Meazza, E. Zeggini, M. Lunt, A. Stevens, E. Shelley, R. Lamb, W. Ollier, et al. 2002. Mutation screening of the macrophage migration inhibitory factor gene: Positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 46:2402-2409.
21. Calandra, T., J. Bernhagen, C.N. Metz, L.A. Spiegel, M. Bacher, T. Donnelly, A. Cerami, and R. Bucala. 1995. MIF as a glucocorticoid-induced modulator of cytokine production. Nature. 377:68-71.
22. Donnelly, S.C., C. Haslett, P.T. Reid, I.S. Grant, W.A. Wallace, C.N. Metz, L.J. Bruce, and R. Bucala. 1997. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat. Med. 3:320-323.
23. Daun, J.M., and J.G. Cannon. 2000. Macrophage migration inhibitory factor antagonizes hydrocortisone-induced increases in cytosolic IκBα. Am. J. Physiol. 279:R1043-R1049.
24. Leech, M., C. Metz, R. Bucala, and E.F. Morand. 2000. Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum. 43:827-833.
25. Mitchell, R.A., C.N. Metz, T. Peng, and R. Bucala. 1999. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). J. Biol. Chem. 274:18100-18106.
26. Hudson, J.D., M.A. Shoaibi, R. Maestro, A. Camero, G.J. Hannon, and D.H. Beach. 1999. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190:1375-1382.
27. Hermanowski-Vosatka, A., S.S. Mundt, J.M. Ayala, S. Goyal, W.A. Hanlon, R.M. Czerwinski, S.D. Wright, and C.P. Whitman. 1999. Enzymatically inactive macrophage migration inhibitory factor inhibits monocyte chemotaxis and random migration. Biochemistry. 38:12841-12949.
28. Swope, M.D., and E. Lolis. 1999. Macrophage migration inhibitory factor: cytokine, hormone, or enzyme. Rev. Physiol. Biochem. Pharmacol. 139:1-32.
29. Kleemann, R., R. Mischke, A. Kapurniotu, H. Brunner, and J. Bemhagen. 1998. Specific reduction of insulin disulfides by macrophage migration inhibitory factor (MIF) with glutathione and dihydrolipoamide: potential role in cellular redox processes. FEBS Lett. 430:191-196.
30. Kleemann, R., A. Hausser, G. Geiger, R. Mischke, A. Burger-Kentischer, O. Flieger, F.J. Johannes, T. Roger, T. Calandra, A. Kapurniotu, et al. 2000. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 408:211-216.
31. Bemhagen, J., R.A. Mitchell, T. Calandra, W. Voelter, A. Cerami, and R. Bucala. 1994. Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). Biochemistry. 33:14144-14155.
32. Panchuk-Voloshina, N., R. Haugland, J. Bishop-Stewart, M. Bhalgat, P. Millard, F. Mao, W. Leung, and R. Haugland. 1999. Alexa dyes, a series of new fluorescent dyes that yield exceptionally bright, photostable conjugates. J. Histochem. Cytochem. 9:1179-1188.
33. Senter, P., Y. Al-Abed, C.N. Metz, F. Benigni, R.A. Mitchell, J. Chesney, J. Han, C.G. Gartner, S.D. Nelson, G.J. Todaro, and R. Bucala. 2002. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc. Natl. Acad. Sci. USA. 99:144-149.
34. Shachar, I., and R.A. Flavell. 1996. Requirement for invariant chain in B cell maturation and function. Science. 274:106-108.
35. Bendrat, K., Y. Al-Abed, D.J. Callaway, T. Peng, T. Calandra, C.N. Metz, and R. Bucala. 1997. Biochemical and mutational investigations of the enzymatic activity of macrophage migration inhibitory factor. Biochemistry. 36:15356-15362.
36. Yamasaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawansihi, B. Seed, T. Taniguchi, T. Hirano, and T. Kishimoto. 1988. Cloning and expression of the human interleukin-6 (BSF2/IFN beta 2) receptor. Science. 241:825-828.
37. Castro, C., Y. Yang, Z. Zhang, and R. Linnoila. 2000. Attenuation of pulmonary neuroendocrine differentiation in mice lacking Clara cell secretory protein. Lab. Invest. 80:1533-1540.
38. D'Andrea, A., H. Lodish, and G. Wong. 1989. Expression cloning of the murine erythropoietin receptor. Cell. 57:277-285.
39. Loddenkötter, B., B. Kammerer, K. Fischer, and U.-I. Flügge. 1993. Expression of the functional mature chloroplast triose phosphate translocator in yeast internal membranes and purification of the histidine-tagged protein by a single metal-affinity chromatography step. Proc. Natl. Acad. Sci. USA. 90:2155-2159.
40. Calandra, T., B. Echtenacher, D. Le Roy, J. Pugin, C.N. Metz, L. Hültner, D.M.D. Heumann, R. Bucala, and M.P. Glauser. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6:164-169.
41. MacKenzie, C., and T. Hirana. 2000. Quantitative analysis of binding affinity and specificity for glycolipid receptors by surface plasmon resonance. Methods Enzymol. 312:205-216.
42. Strubin, M., E.O. Long, and B. Mach. 1986. Two forms of the Ia antigen-associated invariant chain result from alternative initiations at two in-phase AUGs. Cell. 47:619-625.
43. Leech, M., C. Metz, P. Hall, P. Hutchinson, K. Gianis, W. Smith, H. Weedon, S. Holdsworth, R. Bucala, and E. Morand. 1999. Macrophage migration inhibitory factor (MIF) in rheumatoid arthritis. Arthritis Rheum. 42:1601-1608.
44. Ashman, J.B., and J. Miller. 1999. A role for the transmembrane domain in the trimerization of the MHC class II-associated invariant chain. J. Immunol. 163:2704-2712.
45. Sampey, A.V., P.H. Hall, R.A. Mitchell, C.N. Metz, and E.F. Morand. 2001. Regulation of synoviocyte phospholipase A2 and cyclooxygenase 2 by macrophage migration inhibitory factor. Arthritis Rheum. 44:1273-1280.
46. Takahashi, A., K. Iwabuchi, M. Suzuki, K. Ogasawara, J. Nishihira, and K. Onoe. 1999. Antisense macrophage migration inhibitory factor (MIF) prevents anti-IgM mediated growth arrest and apoptosis of a murine B cell line by regulating cell cycle progression. Microbiol. Immunol. 43:61-67.
47. Chesney, J., C. Metz, M. Bacher, T. Peng, A. Meinhardt, and R. Bucala. 1999. An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol. Med. 5:181-191.
48. Wraight, C., P. van Endert, P. Möller, J. Lipp, N. Ling, C.K.N. MacLennan, and G. Moldenhauer. 1990. Human major histocompatibility class II invariant chain is expressed on the cell surface. J. Biol. Chem. 265:5787-5792.
49. Daeipour, M., G. Kumar, M. Amaral, and A. Nel. 1993. Recombinant IL-6 activates p42 and p44 mitogen-activated protein kinases in IL-6 responsive B cell lines. J. Immunol. 150:4743-4753.
50. Henne, C., F. Schwenk, N. Koch, and P. Möller. 1995. Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens. Immunol. 84:177-182.
51. Koch, H., and A.W. Harris. 1984. Differential expression of the invariant chain in mouse tumor cells: relationship to B lymphoid development. J. Immunol. 132:12-15.
52. Lacey, D., A. Sampey, R. Mitchell, R. Bucala, L. Santos, M. Leech, and E. Morand. 2003. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum. 48:103-109.
53. Rosengren, E., R. Bucala, P. Aman, L. Jacobsson, G. Odh, C.N. Metz, and H. Rorsman. 1996. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 2:143-149.
54. Kleemann, R., A. Kapurniotu, R. Mischke, J. Held, and J. Bernhagen. 1999. Characterization of catalytic centre mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81Ser MIF. Eur. J. Biochem. 261:753-766.
55. Cresswell, P. 1994. Assembly, transport, and function of MHC class II molecules. Annu. Rev. Immunol. 12:259-293.
56. Sant, A.J., S.E. Cullen, and B.D. Schwartz. 1985. Biosynthetic relationships of the chondroitin sulfate proteoglycan with Ia and invariant chain glycoproteins. J. Immunol. 135:416-422.
57. Naujokas, M.F., M. Morin, M.S. Anderson, M. Peterson, and J. Miller. 1993. The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell. 74:257-268.
58. Naujokas, M.F., L.S. Arneson, B. Fineschi, M.E. Peterson, S. Sitterding, A.T. Hammond, C. Reilly, D. Lo, and J. Miller. 1995. Potent effects of low levels of MHC class II associated invariant chain on CD4+ T cell development. Immunity. 3:359-372.
59. Lesley, J., R. Hyman, and P. Kincade. 1993. CD44 and its interaction with extracellular matrix. Adv. Immunol. 54:271-335.
60. Arunachalam, B., C. Lamb, and P. Cresswell. 1994. Transport properties of free and MHC class II-associated oligomers containing different isoforms of human invariant chain. Int. Immunol. 6:439-451.
61. II105-NF-κB-dependent transcription program. J. Biol. Chem. 276:27203-27206.
62. Jasanoff, A., G. Wagner, and D.C. Wiley. 1998. Structure of a trimeric domain of the MHC class II-associated chaperonin and targeting protein Ii. EMBO J. 17:6812-6818.
63. Rubinstein, E., F. Le Naour, C. Lagaudriere-Gesbert, M. Billard, H. Conjeaud, and C. Boucheix. 1996. CD9, CD63, CD81, and CD82 are components of a surface tetraspan network connected to HLA-DR and VLA integrins. Eur. J. Immunol. 11:2657-2665.